AR and prostate carcinoma: In addition, platinum agents play a pivotal role in the treatment of prostate cancer that transitions to small-cell carcinoma or neuroendocrine tumors, thus acquiring resistance to hormone therapy and loss of the androgen receptor signaling pathway [34].